Refine by
Disease Risk Articles & Analysis: Older
44 news found
Such properties include anti-inflammatory effects, promotion of brain health, and reduction of cardiovascular risk. Regular intake has been demonstrated to reduce symptoms of depression and anxiety, enhance fetal brain development, and lower heart disease risks by managing cholesterol and blood pressure levels. ...
High-risk disease was defined using the LATITUDE criteria, which includes ≥2 risk factors: a Gleason score of ≥8, ≥3 bone lesions, and the presence of measurable visceral metastasis. Of 1,305 patients in the full analysis set, 1,005 (77%) had high-volume disease, 912 (70%) had high-risk ...
ByBayer AG
The goal of the dental infection control program is to reduce the risk of disease transmission and provide a safe environment for each patient working in a dental clinic or dental patient. ...
Leading a healthy lifestyle is about feeling good about yourself, reducing your risk of disease (and so much more). However, there are cases when you can’t wait too long or simply don’t have time to go to the gym. ...
We are very pleased with today’s outcome as we continue our mission to improve lives of people living with inflammatory diseases.” The product labels of all JAK inhibitors will be updated to include a precautionary approach for patients aged 65 years or above, those at increased risk of major cardiovascular problems (such as heart attack or stroke), ...
Two powerhouse researchers in prostate cancer will change the way we treat the disease, thanks to funding from legendary volunteer fundraisers, the Bird Dogs and the Alberta Cancer Foundation. ...
(Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following: Phase III clinical trial, Flamingo-01, has officially started Multiple sites have begun the screening and enrolling process ...
Our goal is to reproduce the Phase IIb clinical trial results, which showed no metastatic breast cancer recurrences in patients treated with GLSI-100 over 5 years of follow-up, if the patients were treated, followed, and remained disease free over the first 6 months.” About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to ...
In order to increase the public awareness of cardiovascular health and encourage the population to take preventive action by identifying and mitigating the effects of cardiovascular disease (CVD) risk factors in a timely fashion, the online clinic Medon in collaboration with the health technology start-up Longenesis, has published a survey to determine the CVD ...
Abstract Number: TPS1110; Poster Number: 485b; Abstract Title: A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 (Co-authored with Baylor College of Medicine) ...
Despite the availability of SARS-CoV-2 vaccines, there remains a need for oral drugs to treat the infection and prevent severe disease, especially in at-risk individuals. BIT225 has an established human safety profile and has the potential to be an important first-in-class drug for COVID-19 treatment. ...
“The approval of Kerendia offers physicians a new path to protect these vulnerable patients by reducing their risk of cardiovascular events and delaying kidney disease ...
ByBayer AG
Siolta Therapeutics, a clinical-stage biopharmaceutical company developing novel microbiome-based targeted therapeutics, today announced that it was awarded an Advanced Technology Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The grant will provide funding ...
The studies evaluated patients with R/R DLBCL, PMBCL and FL3B, including those with a broad range of histologies and high-risk disease, and patients who received Breyanzi in the inpatient and outpatient setting. ...
The experts of the Anti-Microbial Resistance (AMR) world, including Vaxdyn’s researchers, have been warning about the entrance into a post-antibiotic era or the occurrence of a silent pandemic for years. However, the general public, including health practitioners, did not understand the message or underscored the magnitude of the problem. Recently, a vast network of AMR experts around the ...
(NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that the first patients have been treated in the Level 1 ‘CAPTAIN’ trial. ...
Coala-Life Group AB (publ), a leading company in cloud-based remote monitoring of heart and lung diseases, announces today that the TITAN-DM study – a clinical observational study aimed at increasing knowledge about the incidence of atrial fibrillation in people with diabetes – is now fully recruited with 600 participants. ...
It leaves many with undiagnosed and untreated levels of disease, and a high risk of consequent visual loss and blindness. “Supporting autonomous AI for the diagnosis of diabetic retinopathy and macular edema, which is proven to lack the racial or ethnic bias that plagues many other AI systems, allows for greater access regardless of race, ethnicity, ...
Stockholm, October 7, 2021: Coala Life, a leading company in cloud-based remote monitoring of heart and lung diseases, is now conducting a clinical observational study in collaboration with researchers at the Gävleborg Region, Uppsala University and Karolinska Institute to increase knowledge about the incidence of atrial fibrillation in people with diabetes. ...
According to the ABS task force, the results of their comprehensive literature study resulted in their stating that LDR prostate brachytherapy monotherapy is an appropriate treatment option for low risk and favorable intermediate risk disease. In combination with external beam radiation, it also found LDR brachytherapy is appropriate for ...